BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

PharmaEngine, Inc. 

16F, 237 Sung-Chiang Road

Taipei  Taiwan  104  Republic of China
Phone: 886-2-2515-8228 Fax: 886-2-2515-7558


SEARCH JOBS




Industry
Pharmaceutical






 Company News
PharmaEngine, Inc. Announces Filing By Baxter BioScience Corporation (BAX) Of Marketing Authorization Application Of MM-398 (PEP02) To The European Medicines Agency For Post-Gemcitabine Metastatic Pancreatic Cancer Patients 5/4/2015 9:02:45 AM
PharmaEngine, Inc. Announces Merrimack (MACK) Completed MM-398 (PEP02) New Drug Application Submission To U.S. FDA 4/28/2015 10:37:15 AM
PharmaEngine, Inc. Announces Phase 2 PEPCOL Study Presented At The 2015 American Society of Clinical Oncology GI Of PEP02 (MM-398) In Combination With 5-FU/LV In Unresectable Metastatic Colorectal Cancer 1/21/2015 10:58:16 AM
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015 11:14:02 AM
PharmaEngine, Inc. Will Join Nanobiotix' Pivotal Trial For NBTXR3 In Soft Tissue Sarcoma To Accelerate Its Development In Asia-Pacific 10/8/2014 7:10:22 AM
PharmaEngine, Inc. And Merrimack Amend MM-398 License Agreement 9/26/2014 8:11:08 AM
PharmaEngine, Inc. Announces Achieving Patient Enrollment Goal in the Phase III Metastatic Pancreatic Cancer Study of PEP02 (MM-398) 8/29/2013 10:14:59 AM
PharmaEngine, Inc. Release: Studies of Nanoliposomal Irinotecan (PEP02, MM-398) in Late Stage Pancreatic Cancer and Gastric Cancer Published in British Journal of Cancer and Annals of Oncology 8/28/2013 10:47:42 AM
PharmaEngine, Inc. and Guangzhou BeBetter Medicine Technology Signed a Collaboration and Research Agreement 1/3/2013 9:25:24 AM
PharmaEngine, Inc. Nabs Rights to Nanobiotix's Nanoparticle Radiotherapy Booster for Up to $57 Million 8/6/2012 7:54:44 AM
12